Epigral

Ahmedabad, India Founded: 1995 • Age: 31 yrs Listed
Essential derivatives and specialty chemicals are manufactured for various industries.
Request Access
Report Incorrect Data
Page last updated

About Epigral

Epigral is a publicly listed company based in Ahmedabad (India) founded in 1995 by Anand Patel, Jayanti Patel, Ramesh Patel, Natwarlal Patel, and Ashish Soparkar. Essential derivatives and specialty chemicals are manufactured for various industries. Epigral has raised $11.5 million across 1 funding round from investors including International Finance Corporation. The company has 1,950 employees. Its Indian entity Epigral Limited reported revenue of ₹2,542 Cr. Epigral offers products and services including Chlor Alkali, Hydrogen Peroxide, Epichlorohydrin, CPVC, and Chloromethanes. Its focus areas include Chemicals and Materials, Diversified Chemicals and Speciality Chemicals.

Company details

Epigral Limited was founded in 1995 and is headquartered in Ahmedabad, India. Operations are focused on the production of chemicals utilized across multiple sectors within the Indian market, where a notable presence has been established. Emphasis is placed on safety protocols and quality standards through ongoing employee training and adherence to secure work practices. Various essential and specialty chemicals are supplied to support industrial applications.

  • Headquarters Ahmedabad, India
  • Employees 1,950
  • Founders Anand Patel, Jayanti Patel, Ramesh Patel, Natwarlal Patel, Ashish Soparkar
  • Stage Public
  • Sectors
    Chemicals & Materials
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website epigral.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Epigral Ltd
Operational Areas
Chemicals & Materials → Core & Diversified Chemicals
Key Metrics
  • Market Cap
    ₹3,970 Cr

    EPIGRAL · NSE

  • Share Price
    ₹945.45

    +2.74% today

  • Revenue
    ₹2,527 Cr

    FY 2025-26 · -0.9% YoY

  • EBITDA
    ₹566 Cr

    Margin 22.4%

  • Net Profit
    ₹330 Cr

    FY 2025-26 · -7.5% YoY

  • P/E (TTM)
    14.4x

    P/B 1.7x

  • ROE
    16.1%

    ROCE 15.5%

  • Debt / Equity
    0.28

    Interest cover 18.1x

  • Total Equity Funding
    $11.5M (USD)

    in 1 rounds

  • Latest Funding Round
    $11.5M (USD), Series B

    Jun 2008

  • Investors
    International Finance Corporation
  • Employee Count
    1,950

Products & Services of Epigral

Epigral offers a comprehensive portfolio of products and services, including Chlor Alkali, Hydrogen Peroxide, Epichlorohydrin, CPVC, and Chloromethanes.

Chlor Alkali
Industrial Chemicals

Produces caustic soda and chlorine for various industrial uses.

Hydrogen Peroxide
Specialty Chemicals

Used in paper, textiles, and chemicals as an eco-friendly agent.

Epichlorohydrin
Chemical Derivatives

Key component for epoxy resins and pharmaceuticals from renewable sources.

CPVC
Polymer Materials

Provides resin and compounds for pipe manufacturing in construction.

Chloromethanes
Organic Chemicals

Includes compounds for pharmaceuticals and refrigerant production.

Apps and channels of Epigral

its YouTube channel Epigral Limited has 504 subscribers and 30 videos.

Epigral Limited
YouTube 504 subscribers 30 videos Howto & Style
Open channel

Videos from Epigral

The most watched videos on Epigral's YouTube channel, Epigral Limited (504 subscribers). Click a video to play it here.

Meghmani Finechem Limited - Corporate Film
7.2K views
Epigral Corporate Film
3.4K views
Epigral Brand Film
1.7K views
CNBC TV18 | Midcap Radar | Mr. Maulik Patel, CMD, Meghmani Finechem Ltd
893 views

More on Epigral Limited.

Funding Insights of Epigral

Epigral has successfully raised a total of $11.5M through 1 strategic funding round. The most recent funding activity was a Series B round of $11.5 million completed in June 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $11.5M
  • Total Rounds 1
  • Last Round Series B — $11.5M
  • First Round $11.5M

    (Jun 2008)

  • Investors Count 1

All 1 funding rounds of Epigral with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jun 2008$11.5MSeries B–IFC
–
Valuation history

1 investors in total: 1 institutional.

Investors in Epigral

Epigral has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include International Finance Corporation.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
International Finance Corporation
IFC is focused on private sector development in emerging markets.
1956ifc.org
Premium access

Investor details for Epigral

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Epigral Limited (Epigral)

Epigral Limited is the primary company behind Epigral. The boards of the 6 registered companies of Epigral currently have 23 directors; the longest-serving is Natwarlal Meghjibhai Patel, appointed in 1994. 35 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Natwarlal Meghjibhai Patel
DIN 00027540
Director26 Dec 199431 yrs 10 moMeghmani Chemicals Ltd
Sanjay Surendra Jain
DIN 02337896
CFO07 May 201412 yrs 5 moEpigral Limited
Nirali Bhavinbhai Parikh
DIN 05309425
Director30 Mar 201511 yrs 7 moEpigral Limited
Jayantilal Meghjibhai Patel
DIN 00027224
Designated Partner13 Nov 20187 yrs 11 moArjan Owners Llp, Meghmani Chemicals Ltd
Ashishbhai Natawarlal Soparkar
DIN 00027480
Designated Partner13 Nov 20187 yrs 11 moArjan Owners Llp, Meghmani Chemicals Ltd
Gurjant Singh Chahal
DIN 05133946
CFO05 May 20215 yrs 6 moMeghmani Organics Limited
Manubhai Khodidas Patel
DIN 00132045
Director07 May 20215 yrs 5 moMeghmani Organics Limited, Epigral Limited
Ganapathi Dadasaheb Yadav
DIN 02235661
Director07 May 20215 yrs 5 moMeghmani Organics Limited
Urvashi Dhirubhai Shah
DIN 07007362
Director07 May 20215 yrs 5 moMeghmani Organics Limited
Raju Swamy
DIN 03032679
Director20 May 20215 yrs 5 moEpigral Limited
Kanubhai Shakarabhai Patel
DIN 00008395
Director20 May 20215 yrs 5 moEpigral Limited
Sanjay Khatau Asher
DIN 00008221
Director20 May 20215 yrs 5 moEpigral Limited
Kamlesh Mehta
DIN 02300533
Nodal Officer25 Aug 20224 yrs 2 moEpigral Limited
Varesh Sinha
DIN 03259880
Director28 Aug 20224 yrs 2 moMeghmani Organics Limited
Karana Rameshbhai Patel
DIN 01727321
Whole-time director14 Aug 20233 yrs 2 moMeghmani Organics Limited, Epigral Limited, Meghmani Advanced Sciences Limited, Meghmani Crop Nutrition Limited
Maulik Jayantibhai Patel
DIN 02006947
Director14 Aug 20233 yrs 2 moMeghmani Organics Limited, Epigral Limited, Meghmani Advanced Sciences Limited, Meghmani Crop Nutrition Limited
Ankit Natwarlal Patel
DIN 02180007
Managing Director14 Aug 20233 yrs 2 moMeghmani Organics Limited, Epigral Limited, Meghmani Advanced Sciences Limited, Meghmani Crop Nutrition Limited
Darshan Anandbhai Patel
DIN 02047676
Whole-time director14 Aug 20233 yrs 2 moMeghmani Organics Limited, Epigral Limited, Meghmani Advanced Sciences Limited, Meghmani Crop Nutrition Limited
Kaushal Ashishbhai Soparkar
DIN 01998162
Director14 Aug 20233 yrs 2 moMeghmani Organics Limited, Epigral Limited, Meghmani Advanced Sciences Limited, Meghmani Crop Nutrition Limited
Nikunt Kirit Raval
DIN 10357559
Director07 Nov 20232 yrs 11 moMeghmani Organics Limited
Gaurang Ghanshyam Trivedi
DIN 03020622
Company Secretary23 Apr 20242 yrs 6 moEpigral Limited
Priyanka Vishal Chopra
DIN 10011547
Director28 Feb 20251 yr 8 moEpigral Limited
Nareshkumar Jashvantbhai Prajapati
DIN 09731794
Company Secretary29 Jul 20263 moMeghmani Organics Limited

People of Epigral

33 people are tracked at Epigral (16 in leadership, 17 in team); the tracked headcount is 1,950.

NameRoleGroup
Anand Patel
Co-FounderLeadership
Jayanti Patel
Co-FounderLeadership
Ramesh Patel
Co-FounderLeadership
Natwarlal Patel
Co-FounderLeadership
Ashish Soparkar
Co-FounderLeadership
Maulik Patel
Managing DirectorLeadership
Ankur Singhal
Zonal Sales HeadLeadership
Sanjay Jain
Chief Financial OfficerLeadership
Sarvesh Kumar Gupta
Regional Head North & EastLeadership
Kaushal Soparkar
Executive DirectorLeadership
Ranveer. Thakur
Assistant General Manager EHSLeadership
Kiran Pabani
Deputy General ManagerLeadership
Mansukh Mavani
Senior Vice PresidentLeadership
Dr.mahendra Rane
Business Unit Head -agm (business Development / Sales & Marketing)-europe /apacLeadership
Yashodhan M Chitnis
Vice PresidentLeadership
Vijay Vasudeva
Senior Vice President OperationsLeadership
Nakkina Veerabhadra Swamy
Deputy ManagerTeam
Milind Kotecha
Investor Relations, Corporate Communication And StrategyTeam
Prashant Yadav
Senior Manager Process & TechnologyTeam
Harsh Asondariya
EngineerTeam

13 more people are available in the full profile.

Premium access

Complete people profiles for Epigral

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Epigral

Epigral is a publicly listed company on the NSE with ticker symbol EPIGRAL in India, operating in the Process industries sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date15 Sep 2023
  • Listed onNSE: EPIGRAL
  • Listed entityEpigral Ltd
  • Exchange sectorProcess industries
  • ISININE071N01016
  • Share price₹999.80 (+0.9% on the day) · 2026-10-14
  • Market capitalisation₹4,269 Cr
  • Price to earnings15.9
  • EPS (diluted, trailing year)₹62.82
  • Dividend yield0.51%
  • Volume (last session)24,671

Financials of Epigral

Exchange-reported figures of Epigral Limited, the listed company behind Epigral (NSE: EPIGRAL).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹2,527 Cr
-0.9% YoY
EBITDA
₹566 Cr
-20.4% YoY
Profit After Tax
₹330 Cr
-7.5% YoY
Net Worth
₹2,221 Cr
+16.6% YoY
Total Assets
₹2,813 Cr
+12.4% YoY
Total Debt
₹572 Cr
-3.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue2,5272,5501,9292,1881,551829
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%-
EBITDA566711481689509261
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%
Profit before tax341541291522383161
Net profit330356195353253101
Net profit margin+13.0%+14.0%+10.1%+16.1%+16.3%+12.2%
EPS (₹)76.9582.9147.1485.0360.8424.27
Balance sheet
Total assets2,8132,5032,2231,9511,7221,228
Net worth2,2211,9051,3091,179937684
Total debt572593909769782542
Cash & bank5.4622.196.7915.1125.090.68
Net working capital352343139105137(8.78)
Cash flow
Cash from operations436441398626284229
Cash from investing(355)(262)(401)(437)(455)(197)
Cash from financing(94.48)(164)(7.60)(200)195(31.90)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income6.484.66(0.57)5.561.748.533.673.95
EBITDA136179168103132163173183
EBITDA margin+18.2%+25.4%+22.8%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax87.5813411054.5669.65107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99
Net profit65.0899.7480.9539.1151.2216186.89104
EPS (₹)15.0923.1218.769.0711.8737.2520.1424.25
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,5272,5501,9292,1881,551829611
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%+35.7%-
EBITDA567711481689509261194
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%+31.8%
Profit before tax342540291523383161141
Net profit326352196353253101112
Net profit margin+12.9%+13.8%+10.2%+16.2%+16.3%+12.2%+18.3%
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
Balance sheet
Total assets2,8132,5022,2231,9511,7221,2281,117
Net worth2,2211,9041,3091,179937684583
Total debt572593909769782542526
Cash & bank5.4622.196.7915.0625.040.680.10
Net working capital352343139105137(8.83)(24.82)
Cash flow
Cash from operations436441398626284229165
Cash from investing(355)(262)(401)(437)(455)(197)(363)
Cash from financing(94.48)(164)(7.60)(200)195(31.90)69.41
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income5.824.10(0.57)5.561.748.253.403.86
Total expenses610526568494455443454463
EBITDA136179169103132163173183
EBITDA margin+18.2%+25.4%+22.9%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax86.9213311154.6069.95107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 05 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income6.484.66(0.57)5.561.748.533.673.95
EBITDA136179168103132163173183
EBITDA margin+18.2%+25.4%+22.8%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax87.5813411054.5669.65107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99
Net profit65.0899.7480.9539.1151.2216186.89104
EPS (₹)15.0923.1218.769.0711.8737.2520.1424.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue2,5272,5501,9292,1881,551829
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%-
Other income14.9816.206.607.984.112.19
Total expenses1,9611,8391,4481,4991,041567
Employee cost11697.8181.3168.8551.9941.26
EBITDA566711481689509261
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%
Depreciation16813312410985.9173.54
Interest71.9653.2773.4965.5044.2729.11
Profit before tax341541291522383161
Tax8.7918394.8816913160.02
Net profit330356195353253101
Net profit margin+13.0%+14.0%+10.1%+16.1%+16.3%+12.2%
EPS (₹)76.9582.9147.1485.0360.8424.27
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital43.1443.1496.55152252252
Reserves & surplus2,1781,8611,2131,028684432
Shareholders' funds (net worth)2,2211,9051,3091,179937684
Minority interest0.000.000.000.000.000.00
Secured loans563585908766778538
Unsecured loans9.057.951.352.623.763.76
Total debt572593909769782542
Total liabilities2,8132,5032,2231,9511,7221,228
Assets
Gross block2,9742,9672,4062,3201,4751,424
Net block2,1172,2381,7671,8041,0681,102
Capital work in progress45163.89483158589126
Investments22.7698.1420.5820.550.000.00
Inventories34938826321215453.96
Sundry debtors417232179166256119
Cash & bank balances5.4622.196.7915.1125.090.68
Loans & advances56.0756.1453.4026.2411.407.81
Total current assets827699502420447181
Total current liabilities475355363315310190
Net working capital352343139105137(8.78)
Total assets2,8132,5032,2231,9511,7221,228
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash18.643.1814.2425.090.680.10
Net cash from operating activities436441398626284229
Net cash from investing activities(355)(262)(401)(437)(455)(197)
Net cash from financing activities(94.48)(164)(7.60)(200)195(31.90)
Net change in cash(13.62)15.46(11.06)(10.85)24.410.58
Closing cash5.4622.196.7915.1125.090.68
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-0.9%+32.2%-11.8%+41.1%+87.2%-
EBITDA growth-20.4%+47.7%-30.2%+35.2%+95.0%-
PBT growth-37.0%+86.1%-44.4%+36.3%+138.4%+9997.0%
Net income growth-7.5%+82.5%-44.7%+39.8%+150.7%-
Revenue CAGR (3Y)+4.9%+18.0%+32.5%---
EBITDA CAGR (3Y)-6.3%+11.7%+22.6%---
Profitability & leverage
Net income margin+13.1%+14.0%+10.2%+16.1%+16.3%+12.2%
Return on capital employed+15.5%+25.2%+17.5%+32.0%+29.0%+15.5%
Return on net worth+16.1%+22.7%+16.9%+39.4%+42.2%+21.3%
Debt / equity0.280.470.670.730.820.79
Long-term debt / equity0.190.290.370.470.560.50
Interest cover18.099.2120.5511.2910.4515.50
Efficiency & per share
Fixed asset turnover0.850.950.821.151.070.58
Inventory turnover6.867.838.1311.9614.9115.36
Debtors turnover7.7912.4111.1810.368.276.97
EPS (₹)76.9582.9147.1485.0360.8424.27
Dividend per share (₹)5.006.005.005.000.000.00
Book value per share (₹)514.94441.48301.83257.30174.72113.88
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue746705736597587607628645
Revenue growth (YoY)+27.0%+16.3%+17.3%-7.5%-6.2%-6.9%--
Other income5.824.10(0.57)5.561.748.253.403.86
Total expenses610526568494455443454463
EBITDA136179169103132163173183
EBITDA margin+18.2%+25.4%+22.9%+17.2%+22.5%+26.9%+27.6%+28.3%
Depreciation44.2342.9041.6942.7542.3141.5433.9532.91
Interest10.787.2215.8010.9521.8423.3711.77(0.07)
Profit before tax86.9213311154.6069.95107131154
Tax22.5034.0028.5915.4518.43(53.68)44.4449.99
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,5272,5501,9292,1881,551829611
Revenue growth-0.9%+32.2%-11.8%+41.1%+87.2%+35.7%-
Other income14.9815.216.527.984.112.192.31
Total expenses1,9601,8391,4481,4991,041567416
Employee cost11697.8181.3168.8551.9941.2632.72
EBITDA567711481689509261194
EBITDA margin+22.4%+27.9%+24.9%+31.5%+32.9%+31.5%+31.8%
Depreciation16813312410985.9173.5444.30
Interest71.9653.2773.4965.5044.2729.1111.14
Profit before tax342540291523383161141
Tax8.7918394.8816913160.0228.99
Net profit326352196353253101112
Net profit margin+12.9%+13.8%+10.2%+16.2%+16.3%+12.2%+18.3%
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital43.1443.1496.55152252252252
Reserves & surplus2,1781,8601,2131,028684432331
Shareholders' funds (net worth)2,2211,9041,3091,179937684583
Secured loans563585908766778538526
Unsecured loans9.057.951.352.623.763.760.00
Total debt572593909769782542526
Total liabilities2,8132,5022,2231,9511,7221,2281,117
Assets
Gross block2,9742,9672,4062,3201,4751,424688
Net block2,1172,2381,7671,8041,0681,102440
Capital work in progress45163.89483158589126691
Investments22.8097.1420.5720.620.050.050.00
Inventories34938826321215453.9648.40
Sundry debtors41723217916625611976.45
Cash & bank balances5.4622.196.7915.0625.040.680.10
Loans & advances56.0756.1453.4026.2411.407.817.13
Total current assets827699502419447181132
Total current liabilities475355363315310190157
Net working capital352343139105137(8.83)(24.82)
Total assets2,8132,5022,2231,9511,7221,2281,117
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash18.643.1814.1925.040.680.10129
Net cash from operating activities436441398626284229165
Net cash from investing activities(355)(262)(401)(437)(455)(197)(363)
Net cash from financing activities(94.48)(164)(7.60)(200)195(31.90)69.41
Net change in cash(13.62)15.46(11.01)(10.85)24.360.58(129)
Closing cash5.4622.196.7915.0625.040.680.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-0.9%+32.2%-11.8%+41.1%+87.2%+35.7%-
EBITDA growth-20.2%+47.7%-30.2%+35.2%+95.0%+34.6%-
PBT growth-36.7%+85.8%-44.4%+36.3%+138.4%+14.1%-41.8%
Net income growth-7.4%+79.8%-44.6%+39.8%+150.7%-9.8%-
Revenue CAGR (3Y)+4.9%+18.0%+32.5%+53.0%+29.7%+11.5%+15.9%
EBITDA CAGR (3Y)-6.3%+11.7%+22.6%+52.5%+17.8%+0.8%+10.5%
Profitability & leverage
Net income margin+13.2%+14.0%+10.2%+16.2%+16.3%+12.2%+18.4%
Return on capital employed+15.6%+25.1%+17.5%+32.0%+29.0%+16.2%+15.2%
Return on net worth+16.2%+22.6%+16.9%+39.4%+42.2%+23.9%+34.2%
Debt / equity0.280.470.670.730.810.840.85
Long-term debt / equity0.190.290.370.470.560.600.73
Interest cover18.059.2120.5511.2910.4515.507.44
Efficiency & per share
Fixed asset turnover0.850.950.821.151.070.781.03
Inventory turnover6.867.838.1311.9614.9116.1913.71
Debtors turnover7.7912.4111.1810.368.278.497.94
EPS (₹)77.1982.6847.1285.0460.8424.2726.95
Dividend per share (₹)5.006.005.005.000.000.000.00
Book value per share (₹)514.94441.24301.83257.32174.72113.8889.66

Timeline of Epigral

3 dated milestones of Epigral across 28 years, from founding to its latest funding, stage changes and deals.

  1. Founded Epigral is founded.
  2. Funding First funding round of $11.5M.
  3. IPO Lists on the stock exchange (IPO).

Web traffic of Epigral

The website of Epigral (epigral.com) receives about 3.5K visits a month.

  • Monthly visits
    3.5K

    ▲ 17.9% vs previous month

Top companies in Core & Diversified Chemicals

3 companies that operate in the same segment as Epigral (Core & Diversified Chemicals) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
DFPCL
Manufacturer of fertilizers, industrial chemicals, crop nutrition products, and real estate
1979Pune, Maharashtra, IndiaUSD 1.21 B1,020
Scimplify
Specialty chemicals are manufactured through integrated R&D and production processes.
2023Bengaluru, Karnataka, IndiaUSD 72.97 MUSD 23.86 M
Himadri Chemicals and Industries
Manufactures coal tar and basic industrial chemicals.
1987Kolkata, West Bengal, IndiaUSD 24 MUSD 515.01 M1,161
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Epigral

EPIGRAL: Q2 CONS NET PROFIT 651M RUPEES VS 512M (YOY)
Exchange Update • 3 days ago
EPIGRAL: Q2 EBITDA 1.36B RUPEES VS 1.32B (YOY); Q2 EBITDA MARGIN 18.3% VS 22.53% (YOY)
Exchange Update • 3 days ago
EPIGRAL: Q2 REVENUE 7.4B RUPEES VS 5.9B (YOY)
Exchange Update • 3 days ago
Epigral: Co MD Assures Optimistic View For Second Half Of FY27.
Exchange Update • 3 days ago
Epigral: Co's Cmd Says Capacity Scale-ups To Drive Co's Rs 5,000 Crore Target By Fy31
Exchange Update • 1 month ago
Capacity scale-ups to drive Epigral's Rs 5,000 crore target by FY31: CMD Maulik Patel - The Economic Times
Economic Times • 1 month ago
Epigral Ltd Proposes To Establish New Manufacturing Facility For Epoxy Resin & Formulations At Existing Facility At Dahej
Reuters • 3 months ago
Epigral June-Quarter Consol Net Profit 997.4 Million Rupees
Reuters • 3 months ago
Epigral Ltd Dec-Quarter Consol Net Profit 391.1 Million Rupees
Reuters • 9 months ago
Astral, Epigral to gain from China’s VAT rebate rollback on PVC
Moneycontrol • 9 months ago
Premium access

Complete news archive for Epigral

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Epigral

Epigral was founded in 1995 and raised its 1st funding round 13 years after it was founded.

Epigral is headquartered in Ahmedabad, India. It is registered at Ahmedabad, Gujarat, India.

Epigral is a funded company, having raised a total of $11.5M across 1 funding round to date. The company's 1st funding round was a Series B of $11.5M, raised on Jun 2008.

Epigral has 1,950 employees.

The primary company behind Epigral, Epigral Limited, reported revenue of ₹2,542 Cr for FY 2026, down 1% year on year.

Epigral Limited was founded in 1995 and is headquartered in Ahmedabad, India. Operations are focused on the production of chemicals utilized across multiple sectors within the Indian market, where a notable presence has been established. Emphasis is placed on safety protocols and quality standards through ongoing employee training and adherence to secure work practices. Various essential and specialty chemicals are supplied to support industrial applications.

Epigral offers Chlor Alkali, Hydrogen Peroxide, Epichlorohydrin, CPVC, and Chloromethanes.

Yes, Epigral is publicly traded on NSE under the ticker symbol EPIGRAL.

Epigral has 1 investor. Key investors include International Finance Corporation.

Epigral is associated with 6 legal entities: Epigral Limited, Arjan Owners Llp, Meghmani Chemicals Ltd and others.

The legal entities of Epigral currently have 27 directors, including Jayantilal Meghjibhai Patel, Ashishbhai Natawarlal Soparkar, Natwarlal Meghjibhai Patel and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available